Healthcare Individual Manufacturing Transportation 
FDA Law
DECEMBER 13, 2022
Although on its face the restriction applies to LDTs, collection device manufacturers could, as a consequence, effectively be precluded from continuing to market their specimen collection devices to labs offering LDTs which enable home collection unless they first obtain authorization specifically for home collection.
FDA Law
JUNE 22, 2023
As a result, novel IVD manufacturers are more likely to start with clearance of a prescription test intended for use in clinical settings with the thought that one day in the future, after several years of clinical experience demonstrating safe use, they may return to FDA to seek clearance of an OTC version.
Expert insights. Personalized for you.
72 
Let's personalize your content